GlassScriptPhysician profile
Robyn Wechsler
NPI 1811087869
$4,397.19
in general payments reported to CMS, 2019-2025
16 companies · $516 in 2025
The $516 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $229 · 2021: $929 · 2022: $369 · 2023: $485 · 2024: $1,022 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,043.01 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $804.42 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $769.02 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $455.67 | 2022-2025 | Caplyta |
| Abbvie INC. | $391.44 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $273.20 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $162.72 | 2019-2025 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $158.64 | 2019 | |
| Axsome Therapeutics, INC. | $91.62 | 2024-2025 | Auvelity |
| Neos Therapeutics, LP | $48.51 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $45.33 | 2019-2025 | Relexxii |
| Tris Pharma INC | $43.39 | 2024-2025 | Dyanavel Xr |
| Sage Therapeutics, LLC | $39.60 | 2024-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $33.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.09 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $17.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Wechsler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.